Lu Kuan-Hung, Pan Yi-Chun, Sheen Lee-Yan
Institute of Food Science and Technology, National Taiwan University, Taipei 106, Taiwan.
Department of Hospitality Management, St. Mary's Junior College of Medicine, Nursing and Management, Yilan County 266, Taiwan.
J Tradit Complement Med. 2019 May 3;10(2):166-174. doi: 10.1016/j.jtcme.2019.04.008. eCollection 2020 Mar.
, a medicinal mushroom indigenous to Taiwan, possesses various pharmacological functions. The most recognized ethnopharmacological relevance of is hepatoprotection since it was traditionally used for treating liver disorders by Taiwan aborigines. The aim of this study is to evaluate the hepatoprotective effect of the combination of fruiting body and solid-state cultured mycelia of (LDAC) on carbon tetrachloride (CCl)-induced chronic liver damage in rats. We treated Wistar rats daily with low, medium and high [87.5, 175 and 437.5 mg/kg body weight (bw), respectively] doses of LDAC for 9 weeks. After the first week of treatment, rats were administered 20% CCl (0.5 mL/0.3 kg bw) twice a week to induce liver damage until the treatment ended. The results showed that administration of LDAC by oral gavage significantly reduced the absolute weight of the liver and the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in CCl-treated rats The activities of the antioxidant enzymes glutathione peroxidase (GPx), glutathione reductase (GRd) and catalase (CAT) were increased by LDAC treatment. Moreover, LDAC improved CCl-induced hepatic vacuolization, necrosis and fibrosis in a dose-dependent manner, and no adverse effects were observed in the LDAC-treated groups. Based on the results, LDAC is a promising hepatoprotective agent for preventing and ameliorating CCl-induced chronic liver injury, and this effect might be exerted through activation of the antioxidant defense system.
台湾原生药用真菌具有多种药理功能。其最广为人知的民族药理学关联是肝脏保护作用，因为台湾原住民传统上用它来治疗肝脏疾病。本研究的目的是评估台湾原生药用真菌（LDAC）子实体与固态培养菌丝体组合对四氯化碳（CCl）诱导的大鼠慢性肝损伤的肝脏保护作用。我们每天用低、中、高剂量[分别为87.5、175和437.5毫克/千克体重（bw）]的LDAC处理Wistar大鼠，持续9周。在治疗的第一周后，每周给大鼠两次20% CCl（0.5毫升/0.3千克bw）以诱导肝损伤，直至治疗结束。结果表明，通过灌胃给予LDAC可显著降低CCl处理大鼠的肝脏绝对重量以及血清丙氨酸转氨酶（ALT）和天冬氨酸转氨酶（AST）水平。LDAC处理可提高抗氧化酶谷胱甘肽过氧化物酶（GPx）、谷胱甘肽还原酶（GRd）和过氧化氢酶（CAT）的活性。此外，LDAC以剂量依赖的方式改善了CCl诱导的肝空泡化、坏死和纤维化，并且在LDAC处理组中未观察到不良反应。基于这些结果，LDAC是一种有前途的预防和改善CCl诱导的慢性肝损伤的肝脏保护剂，并且这种作用可能通过激活抗氧化防御系统来发挥。
